A company that supports the process development and manufacturing of live biotherapeutic products (LBPs) needs to know bacteria inside out: not just the potential therapeutic effects of the strains, but how the strains behave under different conditions and in different contexts. A better understanding of mechanisms of action, after all, allows better optimization of the … Continue reading “Biose Industrie and strain characterisation – Growing and developing our service offering through strategic sponsoring of research projects”

Live biotherapeutic products (LBPs), or live microorganisms employed as drugs, are relatively new on the pharmaceutical scene. Yet Biose Industrie CEO Adrien Nivoliez has his eye on the future. According to experts and market research, LBP development and manufacturing are set to grow exponentially as the field matures in the years ahead—and Nivoliez foresees that … Continue reading “How Biose Industrie aims to extend its lead in LBP manufacturing with 30-million Euro investment”

Aurillac, July 16, 2020 – Biose Industrie announced today the closing of a €30 million funding round led by Cathay Capital, alongside the company’s management team, banking partners and the Auvergne-Rhône-Alpes region. Thanks to this funding found, Biose Industrie will benefit from Cathay Capital’s support as it accelerates its development and strengthens its leadership position … Continue reading “Biose Industrie raises EUR 30 million to strengthen its position as the reference CDMO in the field of microbiota”

Contract Development & Manufacturing Organizations (CDMOs) are critical partners for moving ahead with new drug products. But with a growing number of start-up companies working to develop microbiome-based products, are CDMOs ready to take on the challenges of manufacturing a whole new category of ‘living medicines’—live biotherapeutic products (LBPs)? Bharat Dixit, VP, Biopharmaceutical Development & Manufacturing at Morningside … Continue reading “When drug manufacturers take on living medicines”